Algeria’s New Institute for Cell and Gene Therapy Aims to Transform Advanced Healthcare and Biomedical Innovation
BY Dr. Hana Saada
Algiers — Algeria is embarking on one of the most ambitious biomedical projects in its history with the establishment of the Algerian Institute for Cell and Gene Therapy, a flagship facility designed to position the country at the forefront of regenerative medicine, gene therapy and advanced pharmaceutical research in Africa.
The strategic project, whose foundation stone was laid by President Abdelmadjid Tebboune in Rahmania, Algiers, is expected to become the country’s first fully integrated centre combining scientific research, advanced biopharmaceutical production and direct patient care under one institution.
According to Professor Mourad Belkhelfa, Chief Executive Officer of Saidal Group and head of the project, the institute represents a major step toward localising advanced medical technologies, strengthening national healthcare sovereignty and reducing Algeria’s dependence on costly medical treatment abroad.
A Fully Integrated Biomedical Ecosystem
Designed around a comprehensive healthcare and research model, the institute will operate through three complementary pillars.
The first will focus on research and development, bringing together Algerian scientists working both domestically and abroad. Authorities intend to actively involve members of the Algerian scientific diaspora in transferring cutting-edge technologies and expertise, with the objective of building local scientific capacity and developing nationally based innovation.
The second pillar will serve as the institute’s industrial core, dedicated to the production of stem cells, immune cells and advanced cell-based therapies manufactured according to international scientific standards. This component places the project at the intersection of biotechnology and Algeria’s pharmaceutical industry, reinforcing the country’s long-term ambition to expand domestic production of high-value medical treatments.
The third pillar will consist of a specialised clinical centre providing direct care for patients through innovative therapeutic approaches unavailable in Algeria until now.
Expanding Treatment Options for Cancer and Chronic Diseases
Initially, the institute will prioritise patients suffering from advanced cancers who have not responded successfully to conventional chemotherapy or radiotherapy.
Officials say these patients will gain access to next-generation therapeutic options designed to provide new treatment opportunities where traditional interventions have proven ineffective.
However, Professor Belkhelfa stressed that the institute’s mission extends far beyond oncology.
Its activities will also encompass regenerative medicine, an emerging field focused on repairing damaged tissues and organs rather than merely alleviating symptoms. Through regenerative therapies, physicians will seek to address the underlying causes of chronic diseases by restoring biological function.
Gene Therapy for Rare and Inherited Diseases
Gene therapy will constitute another central area of activity.
The institute aims to provide advanced treatments for rare, orphan and inherited diseases, conditions for which many Algerian patients have traditionally sought care overseas.
Among the diseases targeted are beta thalassaemia, sickle cell disease, Gaucher disease, various inherited genetic disorders and several autoimmune diseases.
Stem-cell therapies will also be employed to regulate immune responses, reduce inflammation and stimulate tissue regeneration, opening new therapeutic possibilities for patients suffering from complex chronic conditions.
Introducing Advanced Reproductive Genetics
For the first time in Algeria, the institute plans to introduce advanced genetic screening technologies capable of detecting chromosomal and genetic abnormalities in embryos before implantation.
Officials say the technology will allow clinicians to select healthy embryos during assisted reproductive procedures, significantly improving treatment outcomes.
The institute will also provide specialised treatment for azoospermia, one of the leading causes of male infertility.
According to Professor Belkhelfa, the introduction of these technologies could increase the success rate of infertility treatment from approximately 12% to 56%, while reducing the impact of age as a limiting factor through advanced reproductive medicine.
Reducing Medical Treatment Abroad
One of the institute’s principal objectives is to reduce Algeria’s reliance on overseas medical treatment.
Professor Belkhelfa noted that approximately 60% of the costs associated with treatment abroad stem from hospitalisation and accommodation expenses, costs that could be substantially reduced by providing advanced therapies domestically.
By bringing internationally recognised innovations to Algeria, patients will increasingly be able to access cutting-edge treatments without travelling overseas, while progressively lowering healthcare expenditure over the longer term.
National Expertise and International Standards
The project is being developed primarily through Algerian expertise while simultaneously mobilising highly qualified Algerian researchers working abroad.
Officials describe this strategy as an effort to reverse scientific brain drain by integrating members of the national scientific diaspora into Algeria’s healthcare and research ecosystem.
The institute is also expected to collaborate closely with hospitals and specialised cancer centres across the country.
In particular, authorities plan to expand CAR-T cell therapy programmes to additional oncology centres once the necessary immunological monitoring infrastructure is established.
Because CAR-T therapy requires continuous patient monitoring following treatment, implementation will involve close coordination with the Ministry of Health to ensure appropriate follow-up capacities nationwide.
State Support and Long-Term Sustainability
Given the high cost of advanced cell and gene therapies, officials acknowledged that long-term institutional financing will be essential.
Professor Belkhelfa said President Tebboune has made clear that “a patient’s health has no price,” underscoring the state’s commitment to supporting innovative healthcare projects.
Discussions are currently underway regarding the participation of Algeria’s social security institutions—including the National Social Insurance Fund for Salaried Workers (CNAS)—as well as other public social insurance bodies and Sonatrach’s social services system in financing patient access to these advanced therapies.
The initiative reflects Algeria’s broader strategy of strengthening healthcare sovereignty by investing in high-value biomedical infrastructure while ensuring that innovative treatments become progressively accessible to a larger number of patients.
With its integration of scientific research, pharmaceutical manufacturing and specialised clinical care, the Algerian Institute for Cell and Gene Therapy represents one of the country’s most ambitious investments in medical innovation, positioning Algeria to become a regional leader in regenerative medicine, precision healthcare and advanced biotechnology.
— 𝐄𝐍𝐃 —
Dzair Tube Media Group | Record and Standing
Dzair Tube is a leading Algerian digital journalism platform, delivering high-quality content in Arabic, French, and English. With a daily readership exceeding 500,000, it has established itself among the country’s most influential media organizations.
Recognized for editorial excellence and integrity, Dzair Tube was awarded the President of the Republic’s Prize for Professional Journalist in the Electronic Press category on 22 October 2022. The platform operates from state-of-the-art studios, producing diverse programming across news, sports, culture, entertainment, and religion.
Dzair Tube maintains a robust digital presence, with over 600,000 YouTube subscribers, six million followers across Facebook pages, and more than 70,000 Instagram followers. Its sports daily, Dzair Sport, enjoys over 50,000 daily downloads via its official website, cementing its leadership in multimedia journalism.
Further recognized with the Media Leadership Award by former Minister of Communication Mohamed Laâgab and celebrated at the Hilals of Television awards, Dzair Tube continues to set benchmarks in innovation, influence, and public engagement, serving as a key forum for civic discourse, critical analysis, and public affairs.
Official website: www.dzair-tube.dz | English: www.dzair-tube.dz/en
